Cost of Disorders of the Brain in the Czech Republic

Czech version

Authors: E. Ehler ¹; J. Bednařík ²; C. Höschl ³; P. Winkler ^3,4; M. Suchý ⁵; M. Pátá ⁵
Authors‘ workplace: Neurologická klinika FZS Univerzity Pardubice a Pardubické krajské nemocnice, a. s. ¹; Neurologická klinika LF MU a FN Brno ²; Psychiatrické centrum Praha ³; Přírodovědecká fakulta UK v Praze ⁴; Institut pro aplikovaný výzkum, edukaci a řízení ve zdravotnictví, Praha ⁵
Published in: Cesk Slov Neurol N 2013; 76/109(3): 282-291
Category: Review Article

Overview

Our paper aims to replicate the results of a large „Cost of Disorders of the Brain in Europe“ study conducted and published in 2011 and 2012 by The European Brain Council. The study estimated the prevalence of a broad spectrum of brain diseases and associated costs in various areas – in health care, social services and production losses. A comprehensive database with data for each of the participating European Union countries was developed and included in the analysis. This paper presents the results concerning the Czech Republic. The prevalence of diseases in each country was estimated from the data obtained by searching bibliography and large medical databases (Medline and Web of Science) and the results were then extrapolated to all countries of the European Union. Similar approach was used to estimate the mean costs; the data on the average costs of specific clinical situations in individual countries were subsequently extrapolated to other European Union countries. The study enabled estimation of all costs associated with brain disorders for the entire Europe, individual countries, individual disorders and their sequelae. The results of this study demonstrate that these disorders occur very frequently and affect more than half of the population, that the costs associated with brain disorders are enormous and represent substantial proportion of the Gross Domestic Product (approximately 5%) in Europe and in individual countries and that, so far, these diseases have been overlooked by political and economic authorities of the European Union and individual countries.

Key words:
brain disorders – cost of illness – health care – social service

Sources

1. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21(10): 718– 779.

2. Olesen J, Leonardi M. The burden of brain diseases in Europe. Eur J Neurol 2003; 10(5): 471– 477.

3. Olesen J, Freund TS. European Brain Council: partnership to promote European and national brain research. Trends Neurosci 2006; 29(9): 493– 495.

4. Andlin‑Sobocki P, Jönsson B, Wittchen HU, Olesen J.Cost of disorders of the brain in Europe. Eur J Neurol 2005; 12 (Suppl 1): 1– 27.

5. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B. CDBE2010 study group, European Brain Council. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19(1): 156– 162.

6. Andlin‑Sobocki P, Berg J, Ekman M, Jönsson L, Kobelt G, Lindgren P et al. A review of European studies on the economic burden of brain diseases. Eur J Health Econ 2004; 12: 83– 91.

7. Forsgren L, Beghi E, Oun A, Sillanpää M. The epidemiology of epilepsy in Europe – a systematic review. Eur J Neurol 2005; 12(4): 245– 253.

8. Truelsen T, Piechowski‑ Jozwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol 2006; 13(6): 581– 598.

9. Wimo A, Jönsson L, Gustavsson A, McDaid D, Ersek K,Georges J et al. The economic impact on dementia in Europe in 2008 – cost estimates from the Eurocode project. Int J Geriatr Psychiatry 2011; 26(8): 825– 833.

10. Evers SM, Struijs JN, Ament AJ, van Genugten ML, Jager JH, van den Bos GA. International comparison of stroke cost studies. Stroke 2004; 35(5): 1209– 1215.

11. Goldberg LD. The cost of migraine and its treatment. Am J Manag Care 2005; 11 (Suppl 2): S62– S67.

12. Lepine JP. The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry 2002; 63 (Suppl 14): 4– 8.

13. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 2009; 15(7): 556– 562.

14. Jönsson B. CODE‑ 2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002; 45(7): S5– S12.

15. Halpin DM, Miravitlles M. Chronic obstructive pulmonary diseases: the disease and its burden to society. Proc Am Thorac Soc 2006; 3(7): 619– 623.

16. Tagliaferri F, Compagnone C, Korsic M, Servadei F,Kraus J. A systematic review of brain injury epiedmiology in Europa. Acta Neurochir (Wien) 2006; 148(3): 255– 268.

17. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21(9): 655– 679.

18. Nutt DJ. The full cost and burden of disorders of the brain in Europe exposed for the first time. Eur Neuropsychopharmacol 2011; 21(10): 715– 717.

19. Kalvach P. Mozkové ischemie a hemoragie. 3. Přepracované a doplněné vydání. Praha: Grada Publishing 2010.

20. Sovinová H, Sadílek P, Csémy L. Vývoj prevalence kuřáctví v dospělé populaci ČR – Názory a postoje občanů ČR k problematice kouření (Období 1997– 2011). Výzkumná zpráva. Praha: SZÚ 2012.

21. Dzúrová D, Smolová E, Dragomirecká E. Duševní zdraví v sociodemografických souvislostech. Praha: Univerzita Karlova a Psychiatrické centrum 2000.

22. Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E. Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler 2012; 18(5): 662– 668.

23. Gjerstad L, Gilhus NE, Stovner LJ, Hoff JM. The Norwegian Brain Council („Hjerneradet“) – united efforts are necessary! Acta Neurol Scand Suppl 2013; 196: 1– 4.